Tumor suppressive role of miR-569 in lung cancer.

Oncol Lett

Department of Geriatrics, The First Affiliated Hospital of Dalian Medical College, Dalian, Liaoning 116000, P.R. China.

Published: April 2018

microRNAs (miRs) are targets for genomic aberrations and emerging treatments against cancer. It has been demonstrated that targeting miR-569 may potentially benefit patients with ovarian or breast cancer. However, the exact roles of miR-569 remain unclear in human lung cancer cells. Using the reverse transcription-quantitative polymerase chain reaction (RT-qPCR), it was demonstrated that miR-569 expression was consistently decreased in lung cancer cells. As well as cell proliferation and migration inhibition, apoptosis and cell arrest at the G1 phase were induced following reversion of miR-569 expression in lung cancer cells. The present study demonstrated that miR-569 was able to downregulate FOS and high mobility group A2 mRNA and protein expression using RT-qPCR and western blot analysis. The observed role of miRNA-569 in lung cancer cells in the present study suggested that it may be a novel and promising therapeutic target, and a novel biomarker for detecting lung cancer.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835959PMC
http://dx.doi.org/10.3892/ol.2018.7869DOI Listing

Publication Analysis

Top Keywords

lung cancer
24
cancer cells
16
cancer
8
demonstrated mir-569
8
mir-569 expression
8
cells study
8
mir-569
6
lung
6
tumor suppressive
4
suppressive role
4

Similar Publications

Pulmonary hypertension (PH) increases the mortality of preterm infants with bronchopulmonary dysplasia (BPD). There are no curative therapies for this disease. Lung endothelial carnitine palmitoyltransferase 1a (Cpt1a), the rate-limiting enzyme of the carnitine shuttle system, is reduced in a rodent model of BPD.

View Article and Find Full Text PDF

KRAS is a proto-oncogene that is found to be mutated in 15% of all metastatic cancers with high prevalence in pancreatic, lung, and colorectal cancers. Additionally, patients harboring KRAS mutations respond poorly to standard cancer therapy. As a result, KRAS is seen as an attractive target for targeted anticancer therapy.

View Article and Find Full Text PDF

Early cancer detection substantially improves the rate of patient survival; however, conventional screening methods are directed at single anatomical sites and focus primarily on a limited number of cancers, such as gastric, colorectal, lung, breast, and cervical cancer. Additionally, several cancers are inadequately screened, hindering early detection of 45.5% cases.

View Article and Find Full Text PDF
Article Synopsis
  • Lung cancer has the highest incidence and mortality rates globally, making effective post-surgical mental health support crucial due to associated challenges like anxiety and depression.
  • Traditional Chinese medicine shows promise in improving psychological well-being and physical symptoms after lung cancer surgery, but its effectiveness specifically for mental function recovery needs investigation.
  • The study will systematically review various databases for randomized controlled trials focusing on depression and anxiety after lung cancer surgery, assessing data quality and outcomes using established evaluation tools.
View Article and Find Full Text PDF

Multi-disciplinary treatment of broncho-esophageal fistula in a high-risk single-lung patient.

J Cardiothorac Surg

January 2025

Section of Cardiothoracic Surgery, Department of Heart Disease, Haukeland University Hospital, Jonas Lies vei 65, 5021, Bergen, Norway.

Background: A broncho-esophageal fistula (BEF) is a medical and surgical disaster. Treatment of BEF is often limited to palliative stent treatment that may migrate or cause erosions and tissue necrosis. Surgical repair of BEF is the only established definite treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!